Clinical Analysis Of 30 Patients With Chemotherapy-induced Nausea And Vomiting Who Were Cured By Palonosetron

Objective:To investigate the clinical value of palonosetron that is a next-generation 5-HT3 receptor antagonist.Methods:Collection data of 60 patients with cisplatin chemotherapy in Cancer Center of Shandong Provincial Hospital affiliated to Shandong University, from October 2009 to March 2010, of which 48 cases were lung cancer, ovarian cancer in 12 cases. For lung cancer DP regimen (docetaxel+cisplatin) or the EP regimen (etoposide+cisplatin) was used, TP regimen for ovarian cancer (paclitaxel +cisplatin). According to the order of admission, patients were randomly divided into 2 groups:(1) The application of palonosetron group (test group) and 30 cases; (2) application of ondansetron group (control group) 30 cases. The degree of nausea and vomiting during chemotherapy to control the situation, adverse reactions, drug economics and so on were used for a contrast, and the patient's sex, age, clinical symptoms, past history were analyzed in order to the comparison of chemotherapy-induced nausea and vomiting factors.Results:1. Clinical efficacy:The control rates of Palonosetron (test group) in acute vomiting and delayed vomiting were 100%,86.67%, higher than control group (96.67%,80.0%), but the difference was not significant (P＞0.05).2. In the test group and control group, patients were analyzed with different sex, age, past history and other aspects, for the treatment of chemotherapy-induced nausea and vomiting control rates were not reached statistical significance, but by statistically analysis, female patients with moderate to severe nausea and vomiting were significantly higher than male patients (χ2=3.96, P＜0.05); patients who had previous chemotherapy with moderate to severe nausea and vomiting were significantly higher than the patients for the first time (χ2=5.14, P＜0.05).3. Pharmacoeconomic analysis results:the cost of the test group was composed of 501.5 yuan in contrast to the control group EP regimen costs 908.0 yuan at the same time DP and TP regimen cost 544.8 yuan. The EP regimen for patients, composed of the test was significantly lower than the control group; for DP and TP regimen, the cost of the test group was also lower than the control group, but the difference was not statistically significant (P＞0.05). By the minimum cost analysis, of the test group Cost-effectiveness ratio was 5.79, as Cost-effectiveness ratio was 6.81 of the control group.4. Adverse events in test group and control group were 16 cases and 19 cases, no significant difference between the total (χ2= 0.62, P＞0.05). The main side effects in testl group were headache and dizziness, the control group's main adverse reactions were constipation and bloating, in addition to the incidence of constipation were significantly different (χ2= 8.37, P＜0.05), the remaining differences in the incidence of adverse reactions were no statistically significant (P＞0.05).Conclusions:Palonosetron treatment effect is not inferior to ondansetron, treatment cost is lower than ondansetron, easy to use, and easy to accepted by the patients. It can be used for the first-line treatment in prevention and control of platinum chemotherapy-induced nausea and vomiting, and has good foreground for the clinical application.